| Product NDC: | 50242-060 | 
| Proprietary Name: | Avastin | 
| Non Proprietary Name: | bevacizumab | 
| Active Ingredient(s): | 100 mg/4mL & nbsp; bevacizumab | 
| Administration Route(s): | INTRAVENOUS | 
| Dosage Form(s): | INJECTION, SOLUTION | 
| Coding System: | National Drug Codes(NDC) | 
| Product NDC: | 50242-060 | 
| Labeler Name: | Genentech, Inc. | 
| Product Type: | HUMAN PRESCRIPTION DRUG | 
| FDA Application Number: | BLA125085 | 
| Marketing Category: | BLA | 
| Start Marketing Date: | 20040226 | 
| Package NDC: | 50242-060-01 | 
| Package Description: | 1 VIAL, SINGLE-USE in 1 CARTON (50242-060-01) > 4 mL in 1 VIAL, SINGLE-USE | 
| NDC Code | 50242-060-01 | 
| Proprietary Name | Avastin | 
| Package Description | 1 VIAL, SINGLE-USE in 1 CARTON (50242-060-01) > 4 mL in 1 VIAL, SINGLE-USE | 
| Product NDC | 50242-060 | 
| Product Type Name | HUMAN PRESCRIPTION DRUG | 
| Non Proprietary Name | bevacizumab | 
| Dosage Form Name | INJECTION, SOLUTION | 
| Route Name | INTRAVENOUS | 
| Start Marketing Date | 20040226 | 
| Marketing Category Name | BLA | 
| Labeler Name | Genentech, Inc. | 
| Substance Name | BEVACIZUMAB | 
| Strength Number | 100 | 
| Strength Unit | mg/4mL | 
| Pharmaceutical Classes | Vascular Endothelial Growth Factor Receptor Inhibitors [MoA],Vascular Endothelial Growth Factor-directed Antibody [EPC],Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA] |